# LifeMD, Inc.: Form 10-Q for the period ended Jun 30, 2013

- Company: [LifeMD, Inc.](/companies/lfmd.md) (CIK 948320)
- Form: 10-Q
- Filed: 2013-08-14
- Accepted by EDGAR: Aug 14, 2013, 09:48 ET
- Period: 2013-06-30
- Accession: 0001144204-13-045473
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/948320/000114420413045473/v351402_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/948320/000114420413045473/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-04-01 to 2013-06-30 | $322.9k | us-gaap:Revenues |
| Revenue | 6 months, 2013-01-01 to 2013-06-30 | $553.2k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2013-04-01 to 2013-06-30 | $65.7k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2013-01-01 to 2013-06-30 | $134.8k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2013-04-01 to 2013-06-30 | $257.2k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2013-01-01 to 2013-06-30 | $418.4k | us-gaap:GrossProfit |
| Operating income | 3 months, 2013-04-01 to 2013-06-30 | −$20.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2013-01-01 to 2013-06-30 | −$90.9k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-04-01 to 2013-06-30 | $0 | us-gaap:InterestExpense |
| Interest expense | 6 months, 2013-01-01 to 2013-06-30 | $0 | us-gaap:InterestExpense |
| Net income | 3 months, 2013-04-01 to 2013-06-30 | −$15.9k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2013-01-01 to 2013-06-30 | −$57.3k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2013-04-01 to 2013-06-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2013-01-01 to 2013-06-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2013-01-01 to 2013-06-30 | −$37.9k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2013-06-30 | $111.1k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-06-30 | $332.6k | us-gaap:AssetsCurrent |
| Total assets | at 2013-06-30 | $461.8k | us-gaap:Assets |
| Total liabilities | at 2013-06-30 | $281.7k | us-gaap:Liabilities |
| Shareholders' equity | at 2013-06-30 | $180.2k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 16,117 characters.

### Safe Harbor Declaration

### Overview

We manufacture, distribute and sell natural immune support products. We believe, based on testing and analysis conducted on our behalf, that our beta glucans derived from yeast are superior to other beta glucans. Beta glucans are a natural extract that has been shown through testing and analysis and scientific research to support the immune system. Our core nutraceutical and cosmetic product lines consist of yeast beta glucans in oral and topical applications. Our beta glucan products and manufacturing processes are protected by patents and trade secrets and are compliant with current GMPs. Yeast beta glucans are classified as GRAS by the FDA. Historically, we have sold our products primarily on a word-of-mouth basis through distributors and our website as standalone product lines, as well as business-to-business as dietary supplement and a cosmetic enhancement, and as a feed-additive for animal use. As of 2011, we began exiting this lower-margin market for feed-additive products. Our sales and marketing efforts going forward are concentrated on our oral and topical-use products for healthcare professionals, distributors and direct-to-consumer sales.

Significant factors that we believe could affect our operating results are (i) marketing and advertising expenses; (ii) protection of our intellectual property rights; and (iii) imposition of more stringent government regulations of our products.

Our marketing strategy is to promote sales of our oral and topical-use products, which constitute our core business as we shift from low-margin, feed-additive product sales. We believe that we are well positioned to capitalize on our development of proprietary and patented products and can now focus on commercializing sales on a more meaningful, global basis. We expect that a significant component of our selling, general and administration expenses going forward will consist of marketing and advertising expenses to increase our sales. The primary components of our marketing and advertising expenses may include online sales promotions through our website, trade advertising, direct marketing to nutraceutical companies and industry associations, consumer research and search engine and digital advertising. We expect our selling, general and administrative expenses to increase in absolute dollars as we incur increased costs related to our marketing strategy and growth of our business. These costs, along with the additional costs resulting from our operations as a public reporting company, could impact our future operating profitability.

On February 1, 2013, we hired a Chief Marketing Officer, the first such position in the Company’s history. We are planning to introduce new products that leverage our proprietary knowledge and intellectual property. Though there can be no assurance of success, we believe the tools are in place to execute on our marketing plan.

On April 18, 2013, we filed a Form 8K with the Securities and Exchange Commission detailing our plans to execute a 15 month sales and marketing plan to accomplish increase revenue growth. A copy of this plan, along with an audio copy of our April 25, 2013 conference call, can be accessed at www.immudyne.com.

We historically have expended a significant amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products. We rely on the patent and trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive position in the marketplace. For several years, we were involved in complex litigation regarding patents and licenses critical to our products. In 2010, we prevailed on all major legal matters and reached a favorable settlement. If additional litigation becomes necessary to protect our intellectual property rights, such litigation may be costly, divert our management’s attention away from our core business and have a negative impact on our operations. Furthermore, there is no guarantee that litigation would result in an outcome favorable to us.

Our manufacturing processes are compliant in the U.S. with current cGMPs and our yeast beta glucan products are all natural. Further, yeast beta glucans are designated as GRAS under current FDA regulations. Future government regulations may prevent or delay the introduction or require the reformulation of our products. Some agencies, such as the FDA, could require us to remove a particular product from the market, delay or prevent the import of raw materials for the manufacture of our products or otherwise disrupt the marketing of our products. Any such government actions could result in additional costs to us, including reduced growth prospects, lost sales from products that we are required to remove from the market and potential product liability litigation.

We have limited operating capital and have funded operations in the past through the sales of our products and loans and advances from Mark McLaughlin, our President, and other directors. While we believe that we will begin to generate increased sales, it is likely that we will require additional operating capital. Until we are in a position to obtain such capital from revenues to meet our normal business obligations, the Company will have to depend on sources other than operating revenues to meet our operating and capital needs. No assurance can be given that such sources will be available and no assurance can be given that Mr. McLaughlin or other directors who have in the past willingly funded operations will commit to do so in the future, or that the Company will be successful in its endeavors to raise additional capital.

### Results of Operations

### Three Months Ended June 30, 2013, Compared to the Three Months Ended June 31, 2012

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales:

|  | 2013 $% of Sales |  | 2012 $% of Sales |  |
| --- | ---: | ---: | ---: | ---: |
| Sales | 322,903 |  | 227,566 |  |
| Cost of sales | 65,668 | 20% | 103,802 | 46% |
| Gross profit | 257,235 | 80% | 123,764 | 54% |
| Operating expenses | (277,389) | (86)% | (339,463) | (149)% |
| Loss from operations | (20,154) | (6)% | (215,699) | (95)% |
| Other income (expenses), net | - | -% | 25,000 | 11% |
| Interest (expense) | - | -% | (443) | -% |
| Income tax benefit | 4,300 | 1% | 4,300 | 2% |
| Net loss | (15,854) | (5)% | (186,842) | (82)% |

Sales for the second quarter of 2013 were $322,903, an increase of 42% from $227,566 for the same period in 2012. The increase in sales was attributable to increased demand for topical-use products.

Cost of sales consists primarily of material costs, labor costs and related overhead directly attributable to the production of our products. Total cost of sales decreased 37% to $65,668 in the second quarter of 2013 compared to $103,802 for the same period in 2012. The decrease in cost of sales as a percentage of sales in 2013 compared to 2012 resulted primarily from a reduction in lab and other manufacturing costs.

Gross profit increased 108% to $257,235 in the second quarter of 2013 compared to $123,764 for the same period in 2012. Our gross profit increased due to our large increase in sales and our reduction in lab and other manufacturing costs.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Operating expenses decreased 18% to $277,389, in the second quarter of 2013 compared to $339,463 for the same period in 2012. General and administration expense decreased slightly by 8% to $82,265 in the second quarter of 2013 compared to $89,144 for the same period in 2012. Compensation and related expenses decreased by 9% to $157,837 in 2013, compared to $172,754 in 2012, due primarily to a reduction in stock based compensation. Professional fees decreased 52% to $37,287 in 2013, compared to $77,565 in 2012, as a result of decreased legal fees.

Other income decreased by $25,000 in 2013 due to the timing of licence fee receipts.

Our net loss for the second quarter of 2013 was $15,854 compared to net loss of $186,842 for the same period in 2012, a decrease of $170,988 or 92%. Net loss as a percentage of sales was 5% in the second quarter of 2013 compared to net loss as a percentage of sales of 82% for the same period in 2012.

### Six Months Ended June 30, 2013, Compared to the Six Months Ended June 30, 2012

|  | 2013 $% of Sales |  | 2012 $% of Sales |  |
| --- | ---: | ---: | ---: | ---: |
| Sales | 553,161 |  | 406,102 |  |
| Cost of sales | 134,763 | 24% | 178,963 | 44% |
| Gross profit | 418,398 | 76% | 227,139 | 56% |
| Operating expenses | (509,339) | (92)% | (478,664) | (118)% |
| Loss from operations | (90,941) | (16)% | (251,525) | (62)% |
| Other income (expenses), net | 25,000 | 5% | 31,161 | 8% |
| Interest (expense) | - | -% | (3,371) | 1% |
| Income tax benefit | 8,600 | 1% | 8,600 | 2% |
| Net loss | (57,341) | (10)% | (215,135) | (53)% |

Sales for the six months ended June 30, 2013 were $553,161, an increase of 36% from $406,102 for the same period in 2012. The increase in sales was attributable to increased demand for our topical-use products. Sales to our major customer amounted to $446,310 in 2013, compared to $311,647 in 2012.

Cost of sales consists primarily of material costs, labor costs and related overhead directly attributable to the production of our products. Total cost of sales decreased 25% to $134,763 in the six months ended June 30, 2013, compared to $178,963 for the same period in 2012. The decrease in cost of sales as a percentage of sales resulted primarily from a reduction in lab and other manufacturing costs.

Gross profit increased 84% to $418,398 in the six months ended June 30, 2013, compared to $227,139 for the same period in 2012. Our gross profit increased due to our large increase in sales and our reduction in lab and other manufacturing costs.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Operating expenses increased 6% in the six months ended June 30, 2013, to $509,339 compared to $478,664 for the same period in 2012. General and administration expense decreased slightly by 2% to $147,324 in the six months ended June 30, 2013, compared to $150,175 for the same period in 2012. Compensation and related expenses increased by 24% to $277,987 due primarily to the retention of a chief marketing officer, the first such position in the Company’s history. Professional fees decreased 20% to $84,028 as a result of decreased legal fees.

Other income amounted to $25,000 for the six months ended June 30, 2013 compared to $31,161 for the same period in 2012. The decrease was due the write –off of accounts payable in 2012.

Our net loss for the six months ended June 30, 2013 was $57,341 compared to net loss of 215,135 for the same period in 2012, a decrease of $157,794 or 73%. Net loss as a percentage of sales was 10% for the six months ended June 30, 2013 compared to net loss as a percentage of sales of 53% for the same period in 2012.

### Liquidity and Capital Resources

Our principal demands for liquidity are to increase sales, purchase inventory and for sales distribution and general corporate purposes. We have limited operating capital and intend to meet our liquidity requirements, including purchase of raw materials and the expansion of our business, primarily through cash flow provided by operations. Historically, we also have funded operations through loans and advances from our directors and officers and offerings of equity securities. In 2012 and 2011, we raised $345,883 and $193,500, respectively, through sales of our common stock in private placements, as well as the exercising of stock options. During 2013 we raised $50,000 through the exercise of stock options. We may seek additional financing in the form of loans from banks or our directors and officers, or funds raised through future offerings of our equity or debt, if and when we determine such offerings are required. Any future issuance of equity securities could cause dilution to our shareholders. Any incurrence of indebtedness could increase our debt service obligations and cause us to be subject to restrictive operating and financial covenants.

We had net working capital of $89,948 at June 30, 2013, an decrease of $104,046 from net working capital of $193,994 at June 30, 2012. The ratio of current assets to current liabilities was 1.4 -to- 1 at June 30, 2013.

The following is a summary of cash provided by or used in each of the indicated types of activities during the six months ended June 30, 2013 and 2012:

| Cash provided by (used in): | 2013 | 2012 |
| --- | ---: | ---: |
| Operating activities | $(37,873) | (78,785) |
| Financing activities | 50,000 | 292,567 |

Net cash flow used in operating activities was $37,873 for the six months ended June 30, 2013, compared to net cash flow used in operating activities of $78,875 for the same period in 2012. The decrease in net cash outflow in operating activities was attributable primarily to our selling products we held in inventory that were produced in prior quarters.

Net cash flows provided by financing activities was $50,000 in 2013 as a result of the exercise of stock options.

Net cash flows provided by financing activities in 2012 was $292,567 and consisted of $343,296 from the issuance of common stock offset by $50,729 in the repayment of notes payable.

### Private Placements

In a series of private placement transactions in the six months ended June 30, 2012, we issued 1,843,428 shares of our common stock and 3-year warrants to purchase 914,106 shares of our common stock at $0.40 per share to accredited investors at $0.17 per unit for $313,383.

In a series of private placement transactions in 2011, we issued (i) 621,053 shares of our common stock at $0.2286 per share for $142,000 and (ii) 302,941 shares of our common stock and 3-year warrants to purchase 151,500 shares of our common stock at $0.40 per share to accredited investors at $0.17 per unit for $51,500.

### Indebtedness

From time to time, our directors, officers and other related individuals have made short-term advances to us for our operating needs. During the year ended December 31, 2012, notes payable due to officer and other related individuals totaling $50,729 were repaid and the balance of notes payable and amounts due to officer, aggregating $311,443, were converted to common stock. Interest expense on notes payable amounted to $3,371 for the year ended December 31, 2012.

We are subject to a royalty agreement pursuant to which we are required to pay a monthly royalty of 8% on all sales of certain skin care products up to $227,175. At June 30, 2013, we included $131,000 in accounts payable and accrued expenses relating to this royalty agreement, with the remaining commitment under the royalty agreement at approximately $80,000. Our President, Mr. McLaughlin, has a 60% interest in the royalties paid under the agreement and has voluntarily deferred payments due without interest until we have the financial wherewithal to pay such royalties.

### Going Concern

Based on the Company's cash balance at June 30, 2013 and projected cash needs for the remainder of 2013, management estimates that it will need to raise additional capital to cover operating and capital requirements for the 2013 year. Management plans on raising the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company.

The Company’s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors or the issuance of additional shares of common stock.

## Controls and procedures

As filed, 2,712 characters.

### Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer (“PEO”), who is also our Principal Financial Officer (“PFO”), of the design and effectiveness of our “disclosure controls and procedures” (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our PEO/PFO concluded that as of the end of the period covered by this report, these disclosure controls and procedures were not effective. The conclusion that our disclosure controls and procedures were not effective was due to the presence of the following material weaknesses in disclosure controls and procedures which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment as the Company had only one officer; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines; and (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no written whistleblower policy. Our PEO/PFO plans to implement appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy once funds are available; and (iii) implement sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended June 30, 2013, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

## Risk factors

As filed, 145 characters.

You should consider carefully the factors discussed in the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2012.

Filed Aug 14, 2013.
Source: SEC EDGAR, the filing index for accession 0001144204-13-045473. Last ingested by Listed: Nov 13, 2026, 16:33 ET. No prices; not investment advice.
